about
Deferasirox for managing transfusional iron overload in people with sickle cell diseaseDeferasirox for managing iron overload in people with thalassaemiaDeferasirox for managing transfusional iron overload in people with sickle cell diseaseProfile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromesIron homeostasis and toxicity in retinal degenerationIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesFanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.New therapeutic targets in atrophic age-related macular degeneration.Cutaneous porphyrias part II: treatment strategies.Deferasirox for managing iron overload in people with thalassaemia.Zinc deficiency-induced iron accumulation, a consequence of alterations in iron regulatory protein-binding activity, iron transporters, and iron storage proteins.Absolute oral bioavailability and disposition of deferasirox in healthy human subjects.Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
P2860
Q24194549-B409EAF7-3C8A-49AE-ACE7-1818720561A1Q24203718-B8E6246F-EEBA-4B2B-ABBB-F162FC6BD85AQ24236463-03008DDF-52F5-4EA7-9684-B3DA78FB76DDQ26771519-E1C60AA7-5D6E-4F94-BEEC-8F8561F87A59Q28252419-D6C17D08-3B79-48BD-B22E-0969BFCBFB4FQ28388335-5B600DBF-FA35-45F4-A6E6-6E5ABFEE8042Q33392822-1535A0E3-9FD8-46D5-A083-451022DAE2E1Q35077670-C009594E-B3D8-4895-B70B-7E6F9BAEA05EQ35987342-9F7E389B-3FD6-4641-8D5B-1FE23988C70CQ36804427-2FB4DCAD-A3BA-4989-98F3-C0822EB5A201Q38153429-97C6B523-AD0A-4FAE-BCCC-958410EBAF74Q38624033-6455971F-1040-4636-B02C-531EAE693044Q42819443-E88ADA3F-77A5-44FF-A925-4A98E8ED079FQ46570618-F06F1836-F6A0-4526-9820-ECB64536F7BEQ46748354-5E1CEC2C-0FBD-4FFC-BA8D-7AEE89743906
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Deferasirox--an oral agent for chronic iron overload.
@ast
Deferasirox--an oral agent for chronic iron overload.
@en
type
label
Deferasirox--an oral agent for chronic iron overload.
@ast
Deferasirox--an oral agent for chronic iron overload.
@en
prefLabel
Deferasirox--an oral agent for chronic iron overload.
@ast
Deferasirox--an oral agent for chronic iron overload.
@en
P2860
P356
P1476
Deferasirox--an oral agent for chronic iron overload.
@en
P2093
Heidi E Vanorden
Tracy M Hagemann
P2860
P304
P356
10.1345/APH.1G566
P407
P577
2006-05-30T00:00:00Z